Dexamethasone is a life-saving coronavirus drug, claim Oxford scientists

News Network
June 16, 2020

University of Oxford researchers have claimed that a cheap and widely available drug called dexamethasone can help save the lives of patients who are seriously ill with coronavirus.

Scientists working on the Recovery Trial found the drug could help patients on ventilators and oxygen, but had no effect on those who did not need help breathing.

“Based on these results, one death would be prevented by treatment of around eight ventilated patients or around 25 patients requiring oxygen alone,” researchers said in a statement.

Matt Hancock, the health secretary, tweeted: “This global first exemplifies the power of science.”

“I’m absolutely delighted that today we can announce the first successful clinical trial for a treatment for Covid-19,” Mr Hancock said.

Recovery Trial experts said a randomised group of 2,104 patients was given 6mg of dexamethasone per day for 10 days, while another group of 4,321 were given normal treatment.

Dexamethasone reduced deaths by one-fifth in patients on oxygen feeds and by one-third in those who needed a ventilator to breathe, preliminary results showed.

Mr Hancock added: “This is a huge step forward and it’s because we’ve backed the science.”

Martin Landray, professor of medicine and epidemiology at the Nuffield Department of Population Health, University of Oxford, and one of the trial’s chief investigators, said in a statement: “These preliminary results from the Recovery Trial are very clear – dexamethasone reduces the risk of death among patients with severe respiratory complications.

“Covid-19 is a global disease – it is fantastic that the first treatment demonstrated to reduce mortality is one that is instantly available and affordable worldwide.”

Comments

kushal kumar
 - 
Thursday, 18 Jun 2020

Trials  of  drug  dexamethasone   in  Covid-19  cases   have  brought  success  in  saving  lives  ,  claim  Oxford  University  scientists  on  16 June  2020. 

              According  to  news  reports  on  16 June  , 2020  ,   Oxford  University  Scientists  have  conducted  trials  on  anti-inflammatory  steroid  Dexamethasone   in  Covid-19  cases.  Results  released  by  the   Oxford  University    on  16  June  2020  say  that  the   low-cost  and  easily  available  drug  saves  the  people  seriously  infected  by   Coronavirus  ,  cuts  the  death  risk  by  a  third  for  those  on  ventilators  and  by  a  fifth  for  those  on  oxygen.  The  commentary   on  the  drug   reads  like  this  :-

“  This  is  a  tremendous  news  today  from  the  recovery  trial  showing  that  dexamethasone   is  the  first  drug  to  reduce  mortality  from  Covid-19.  It  is  particularly  exciting  as  this  is  an  inexpensive  widely  available  medicine.  This  is  a  ground  breaking  development  in  our  fight  against  the  disease  and  the  speed  at  which  researchers  have  progressed  finding  an  effective  treatment  ,  is  truly  remarkable.  It  shows  importance  of  doing  high  quality  clinical  trials  and  basing  decisions  as  the  results  of  those  trials”. 

               Covid-19  has  taken  into  its  grip   the  entire  world  during  first  half  of  the  year  2020  ,  infecting   lacs  and  killing  also  lacs  of   its  patients.  In  the  absence  of  an  effective  drug  or  vaccine  ,  people  had  no  choice  other  than   to   look   up   to  the  heavens  or   scientists  to  come  with  some  cure.  And  the  drug  described  here  is  the  first  one  to  respond  to  the  prayer   of  the  global  community  ,  it  seems.     As  regards  a  vaccine  ,   only  few  are  claiming  that  it  can  come  by  the  end  of  the  present  year  2020.  Rather   ,  some  are  of  the  view  that  it  may  take  a  larger  part  of  the  year  2021  and   could   even  go    to  mid-2022.   Whatever  that  scenario  about  prospect  of  arrival  of  vaccine  to  treat  Covid-19  may  be   ,  the  news  that  was  broken   on  16  June  2020   by   the  Oxford  University   scientists   in  relation  to   drug  dexamethasone   would  have  sent  a  wave  of   strength  and  hope   among   people  world-wide.  And  this  Vedic  astrology  writer  was  spirited  for  another  reason  as   well   -  a  prediction  of   when  some  relief   by  way  of  drug  to  fight  Covid-19   may  appear  ,   having  come  accurate  in   the   claim  announced  by  Oxford  University   on  16 June  2020.  This  writer  had  ,   based   on  interpretation  and  application   of  Vedic  astrology  ,   contributed  in  early  April  ,  2020   an  opinion  piece     - “  Some  searchlight  on  way  out  of  Covid-19  presently  tormenting  mankind” -   to  a  number  of   newspapers.  It  was  also  contributed  on  11  April  ,  2020   using  the  ‘ comments’   column  of  article  -‘ Heard  Charles  took   Ayurveda  treatment-based  Ayush  drugs  for   Covid-19’  -   at   theprint.in/india/looking-at-evidence-based-ayush-medicines-to-treat-covid-19-minister-shripad-naik/393407/.   The  text  in  the  opinion  piece  related  to  the  claim  of  success  announced  by  Oxford  University  scientists  on  16 June  ,  2020  ,  reads  like  this  :- 

“  So  reading  in  between  the  lines  ,  it  can  be  said  that  some  effective  drug   or  remedy  can  arrive  by   mid   or  towards   the  last  week  of  June  2020   to   provide  some  relief  during  July  to  September  2020 ,  to  some  good  extent”.

The  point  this  writer  wants  to  share  with  readers  world-wide  is  that   yes  ,  a  drug   envisaged  in  the  aforesaid  prediction  has  appeared  on  the  horizon  in  the  claim  announcement  of  Oxord  University  scientists  on  16  June ,  2020. 

Bio  :-

 

Kushal  kumar  ,

202-GH28  ,  Mansarovar   Apartments  ,

Sector  20  ,  Panchkula-134116  ,  Haryana,

India.

Note  :-  This  writer’s    significant  predictive  work  covering   2020   about   the  U.S.  and  Italy

 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 19,2020

Feb 19: Bavaguthu Raghuram Shetty was once a typical billionaire with a taste for the high-life.

He splurged on a private jet, vintage cars and two entire floors of the Burj Khalifa, the world’s tallest skyscraper. His website shows him hobnobbing with politicians, Bill Gates and Bollywood royalty.

“The thrill of speed and freedom makes me love cars,” Shetty, 77, told local reporters last year.

Shetty had more than enough money -- at least on paper -- to afford such a lifestyle from companies he helped found, including hospital operator NMC Health Plc and financial services firm Finablr Plc. On Dec. 10, his stakes in the public companies were valued at $2.4 billion, making up the bulk of a fortune spanning education, hospitality and one of the world’s oldest tea companies.

Then, a week later, Carson Block came along.

Block’s investment firm, Muddy Waters, issued a report criticizing NMC’s accounts and disclosing a short position. Since then, Muddy Waters’s scrutiny has snowballed into a troubling scenario for Shetty that sheds light on his complex share arrangements and casts doubts about his net worth. His holdings in Finablr and NMC are worth $885 million, but Shetty’s fortune may now be just a fraction of that, depending on the size of his borrowings.

Filings this month show that Shetty pledged a quarter of his NMC stake against loans with First Abu Dhabi Bank and Zurich-based Falcon Private Bank. Two other shareholders may own half of his reported stake. Another lender -- Al Salam Bank Bahrain -- has already sold some of those shares to enforce security over a loan for Shetty, and NMC said Tuesday that First Abu Dhabi Bank sold another chunk earlier this month.

The situation “seems to have gone beyond some of the issues that Muddy Waters focused on initially,“ said Gavin Launder, a fund manager at Legal & General Investment Management, who owned shares in NMC until October. “The increased scrutiny has unearthed other issues.”

Law firm Herbert Smith Freehills has launched a review of Shetty’s holdings at his request, a spokesperson for the Indian-born businessman said, declining to comment further until the analysis is completed. Shetty resigned Sunday as NMC’s chairman.

In its Dec. 17 report on NMC, Muddy Waters hinted at potential overpayment for assets, inflated cash balances and understated debt. Shares of the United Arab Emirates’ biggest private health-care provider have since plunged 67%, and the firm is now the focus of takeover speculation. The sell-off also spread to Finablr, whose stock has tumbled 64% in that span.

NMC has disputed Muddy Waters’s claims, and the company hired former FBI Director Louis Freeh to conduct an independent review of the short seller’s allegations. Meanwhile, local regulators “are making inquiries with the relevant parties,” a spokesperson for the U.K.’s Financial Conduct Authority said.

Shetty is hardly the only ultra-wealthy person to leverage his assets. Elon Musk has used his shares in Tesla Inc. to obtain personal loans, while Oracle Corp. Chairman Larry Ellison has put up millions of the company’s shares to fund a lavish lifestyle that includes trophy properties, America’s Cup teams and the Indian Wells tennis facility in California.

But such deals can also sour, as demonstrated by Shetty’s lenders selling shares his investment firm pledged. He and his advisers are investigating details of the sales as part of their legal review, according to filings.

To complicate matters, Shetty pledged another batch of NMC stock in 2018 as part of a so-called equity collar arrangement with Goldman Sachs Group Inc. that uses options to limit the impact from share moves. Last month, he also pledged most of his stake in Finablr to refinance a loan from the company’s takeover of foreign-exchange firm Travelex for about $1.2 billion.

BRS Ventures Investment, the UAE-based holding company for most of Shetty’s assets, doesn’t report consolidated financials, preventing a complete analysis of his net worth. His other assets include a catering company, a waste-management firm and pharmaceutical business Neopharma, which four months ago was in the early stages of planning for an initial public offering.

Block, 43, earned his reputation as a short seller a decade ago through targeting U.S.-listed Chinese companies that he claimed were frauds. More recently, his San Francisco-based firm focused on British litigation-finance firm Burford Capital Ltd. and Japanese biotech stock PeptiDream Inc. Short sellers seek to benefit from a decline in a company’s share price.

Shetty founded NMC in 1975 after moving to Abu Dhabi from his native India. He created Finablr two years ago to consolidate his financial brands before listing it on the London Stock Exchange in 2019.

Block said he didn’t anticipate NMC’s shareholding drama.

“I wouldn’t have been able to predict that we’d get these bizarre disclosures about unclear share ownership coming out of the company,” he said in a Feb. 13 phone interview. “This has been obviously a more dramatic unraveling than we usually see.”

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 8,2020

Udupi, Jan 8: Senior journalist Raviraj Valalambe passed away due to suspected cardiac arrest on Tuesday night at his residence in Kinnimulki, here. He was 50.

Raviraj was rushed to a hospital after he complained of chest pain. He breathed his last on way to medical facility.

He was the director of Prime TV, a local Kannada news channel.

He had worked as a reporter for ETV and Suvarna News channel earlier.

He is survived by wife and two daughters.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 19,2020

Bengaluru, Jun 19: COVID-19 cases in Karnataka has breached the 8,000 mark, as the state on Friday reported 337 new cases and ten related fatalities, taking the total number of infections to 8,281 and death toll to 124.

Also, total discharges in the state breached 5,000 mark, with 230 patients getting discharged in a day after recovery.

As of June 19 evening, cumulatively 8,281 COVID-19 positive cases have been confirmed in the state, which includes 124 deaths and 5,210 discharges, the health department said in its bulletin.

It said out of 2,943 active cases, 2,865 patients are in isolation at designated hospitals and are stable, while 78 are in ICU.

The ten dead include- seven from Bengaluru urban, two from Bidar and one from Vijayapura.

Out of the 337 new cases, 93 are returnees from other states, majority of them from neighboring Maharashtra,while 11 are those who returned from other countries.

The remaining cases include contacts of patients earlier tested positive, those with history of SARI and ILI, among others.

Among the districts where the new cases were reported, Bengaluru accounted for 138 cases, followed by Kalaburagi 52, Ballari 37, Hassan 18, Dakshina Kannada 13, Davangere 12, Udupi 11; Bidar 10, six each from Mysuru and Koppal, four each from Yadgir, Kolar and Bengaluru rural, three each from Mandya, Dharwad, Chikkaballapura, Bagalkote and Ramanagara, two each from Tumakuru and Chikkamagaluru, and one each from Belagavi, Uttara Kannada and Shivamogga.

Kalaburagi district tops the list of positive cases, with 1,126 infections, followed by Udupi 1,050 and Bengaluru urban 982.

Among discharges Udupi tops the list with 944 discharges, followed by Kalaburagi 646 and Yadgir 477.

A total of 4,84,060 samples were tested so far, out of which 10,553 were tested on Thursday alone.

According to the bulletin,4,64,338 samples have been reported as negative, and out of them 9,862 were reported negative today.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.